In this study, we investigated whether two proteins whose expression is increased in the brains of AD patients, the purinergic receptor P2X7R and the ectoenzyme TNAP [17,18,22,23], are also altered in the plasma of these patients and therefore could potentially be used as plasma biomarkers to predict the evolution of the disease. This evidence concerns the gene ALPL and Alzheimer disease.